Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

The incidence of mental illness was higher among women with MS during both the prenatal period (incidence ratio [IR] 1.26, 95 ...

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...